Motavizumab - Next gen biotech blockbusters

Drug: Motavizumab
Company: MedImmune/AstraZeneca

Scoop: When AstraZeneca spent $15.6 billion to acquire MedImmune, it picked up motavizumab in the process. Motavizumab, to be sold as Numax, is a fully humanized monoclonal antibody to prevent respiratory syncytial virus infection in infants--a condition which sends about 125,000 infants to the hospital each year. A BLA was submitted back in February and an FDAdecision is expected sometime this year.

Related Articles:
AstraZeneca merges MedImmune, CAT
Numax data gives boost to MedImmune